AlphAIalphai — Financial news for AI agents
finance.yahoo.comAUG 242 min read$NEO

NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?

NeoGenomics (NEO) stock rose 22.3% in the past month, hitting a 52-week high of $17.08. The company beat earnings estimates in the last four quarters. For the current fiscal year, it expects $0.18 EPS on $802.67M revenue, with a 50% EPS growth. NEO has a Zacks Rank of #2 (Buy) and a VGM Score of B. Halozyme Therapeutics (HALO) is also highlighted as a strong performer in the industry.

Original reporting
finance.yahoo.com
Published Aug 24, 2026, 1:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 2:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run? — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$NEOBullishMed
01

Why it matters

The earnings beat reinforces the bullish narrative, but valuation metrics warn of overextension.

02

Market read

Earnings beat and guidance may drive short‑term price appreciation, while high multiples could temper longer‑term gains.

03

What to watch

High PEG and premium valuation could limit upside if growth slows.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

NeoGenomics has a track record of earnings surprises and a Zacks Rank #2 (Buy).

Company-level read

Ticker impact

$NEOBullishHigh confidence
Context

NeoGenomics reported EPS $0.05 vs $0.03 estimate and provided FY guidance of $0.18 EPS on $802.67M revenue.

Expected impact

Potential short‑term rally, target +10% over next 2‑3 weeks.

Evidence & confidence

Beat of consensus and strong forward‑looking earnings growth indicate positive earnings momentum.

Market effects

Sector

Highlights strength in the Medical – Biomedical and Genetics sector, may lift peers.

Regional

Positive for US biotech stocks, modest effect on broader market.

Global

Limited to biotech investors; no global macro impact.

Counterpoint

What could challenge this read

Valuation appears stretched (94.3x FY EPS) suggesting potential pullback risk.

Key entities

  • company
    NeoGenomics, Inc.

    US‑listed molecular diagnostics firm.

Read at source← All news

Related articles

JUL 30
$NEOHighAI 9/10

NeoGenomics Q2 Earnings Call Highlights

NeoGenomics (NASDAQ: NEO) reported Q2 adjusted gross margin of 48.1% and adjusted EBITDA of $14.4 million. It raised 2026 revenue guidance to $802 million to $806 million and adjusted EBITDA to $56 million to $58 million. Management discussed RaDaR ST and PanTracer LBx reimbursement progress, NovaSeq X transitions, and a $316 million convertible note raise. Cash was $145.5 million.

yahoo.com7 min
JUL 30
$SPRCHighAI 8/10

Top Biotech Gainers: SPRC On Watch, AVTR, NEO Boost Full-Year Outlook, SMTI Scooped Up

Biotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.

rttnews.com3 min
JUL 29
$NEOMedAI 9/10

Why NeoGenomics (NEO) Stock Is Up Today

NeoGenomics (NEO) shares rose 15.8% after the company reported Q2 2026 adjusted EPS of $0.05 on revenue of $201.7 million, beating Wall Street forecasts of $0.03 and $197.3 million. NeoGenomics also raised full-year guidance to about $804 million revenue and $0.19 adjusted EPS.

financialcontent.com4 min
JUL 29
$NEOMedAI 8/10

NeoGenomics Inc (NEO) Q2 2026 Earnings Call Highlights: Strong Revenue Growth

NeoGenomics (NEO) reported Q2 2026 revenue of $201.7 million, up 11% year over year, with clinical revenue up 14% and NGS revenue up 26%. Adjusted gross margin rose to 48.1% and adjusted EBITDA increased to $14.4 million. Nonclinical/pharma revenue fell 26%. 2026 guidance was raised to $802-$806 million revenue and $56-$58 million adjusted EBITDA.

yahoo.com3 min
JUL 28
$NEOMed

NEOGENOMICS INC (NEO): Results of Operations and Financial Condition

NEOGENOMICS INC (NEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a99-106302026earningsrelea.htm EX-99.1 Document Exhibit 99.1 NeoGenomics Reports Second Quarter 2026 Results Total revenue increased 11% YoY to $202 million Clinical services revenue grew 14%, with NGS revenue growth of 26% Company raises full-year 2026 revenue and adju

SEC EDGAR 8-K6 min